Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical tri... Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. Show more
Achieved $11 million in ZURZUVAE® (zuranolone) collaboration revenue during the third quarter of 2024 (50% of the net revenue recorded by Biogen), representing 49% growth from the second...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.45 | -23.2744783307 | 6.23 | 6.28 | 4.735 | 798616 | 5.26051427 | CS |
4 | -3.02 | -38.7179487179 | 7.8 | 8.7 | 4.735 | 833673 | 6.45033742 | CS |
12 | -3.4 | -41.564792176 | 8.18 | 8.7 | 4.735 | 690728 | 6.97188934 | CS |
26 | -6.92 | -59.1452991453 | 11.7 | 13.47 | 4.735 | 906985 | 9.41001621 | CS |
52 | -14.48 | -75.1817237799 | 19.26 | 28.26 | 4.735 | 932988 | 14.69100089 | CS |
156 | -36.08 | -88.3015173764 | 40.86 | 59.99 | 4.735 | 815971 | 26.44563042 | CS |
260 | -141.87 | -96.7405386976 | 146.65 | 159.99 | 4.735 | 815498 | 38.73894644 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.